Direct Anterior Approach for Femoral Neck Fractures

October 30, 2024 updated by: Helse Møre og Romsdal HF

A Randomized Controlled Trial Comparing Direct Anterior Approach to Direct Lateral Approach in Patients Receiving a Total Hip Arthroplasty for Femoral Neck Fracture - a 1 Year Follow-up Study

The primary objective is to examine if in patients with a dislocated femoral neck fracture who receive a total hip arthroplasty, direct anterior approach will give a better result in terms of mobilization, function and pain in the first weeks and months postoperatively, than direct lateral approach.

Study Overview

Detailed Description

first included patient 23th November 2018

Study Type

Interventional

Enrollment (Actual)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kristiansund, Norway
        • Kristiansund Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Dislocated femoral neck fracture

Exclusion Criteria:

  • Infection around the hip (soft tissue or bone)
  • Pathologic fracture
  • Excessive alcohol or substance abuse that most likely will give reduced compliance
  • Patients with any fractures of the long bones in the lower extremity, fracture of the spine, and/or intra-thoracic or intra-abdominal injury (i.e., multiple trauma). Because the outcomes and clinical course of patients with multiple trauma may be quite different from a non-trauma patient.
  • Bedridden patients/non-walkers
  • Patients with an underlying illness that doesn't have life expectancy beyond six months
  • In case of severe cognitive impairment where the patients are not able to give their informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Direct anterior approach
total hip arthroplasty with direct anterior approach
total hip arthroplasty with DAA
Other Names:
  • DAA
Experimental: Direct Lateral Approach
total hip arthroplasty with direct lateral approach
total hip arthroplasty with DLA
Other Names:
  • DLA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in Timed Up and Go Test (TUG) between the groups
Time Frame: 6 weeks postoperatively.
It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
6 weeks postoperatively.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
radiological results 1.
Time Frame: postoperative, 3,12 months.
We will look at the offset of the hip prosthesis.
postoperative, 3,12 months.
radiological results 2.
Time Frame: postoperative, 3,12 months.
We will look at alignment of the stem. Femoral component angulation between 3° varus and 3° valgus relative to the femoral shaft axis will be considered neutral. Positioning outside this references will be graded as varus or valgus
postoperative, 3,12 months.
radiological results 3.
Time Frame: postoperative, 3,12 months.
We will look at quality of stem cementation by Barrack
postoperative, 3,12 months.
radiological results 4.
Time Frame: postoperative, 3,12 months.
We will look at leg length. It will be measured using the vertical height from the interteardrop line.
postoperative, 3,12 months.
radiological results 5.
Time Frame: postoperative, 3,12 months.
We will look at inclination of the cup.It will be measured in reference to the interteardrop line.
postoperative, 3,12 months.
radiological results 6.
Time Frame: postoperative, 3,12 months.
We will look at anteversion of the cup. It will be measured using the ischiolateral method.
postoperative, 3,12 months.
complications
Time Frame: Within the first year postoperatively.
periprosthetic fractures, dislocation, implant failure, neurovascular injury, infection. abductor failure, neurapraxia of LFCN), and mortality
Within the first year postoperatively.
Difference in Forgotten Joint Score for hip (FJS-12) between the groups
Time Frame: 2,6,12 weeks, and 1 year
12 questions. Every question is scored 1 (never) to 5 (mostly) according to the selected response categories. Thus, the raw score ranges from 12 to 60. The raw score is linearly transformed to a 0-100 scale and then reversed to obtain the final score. Final score = 100 - ((sum(item01 to item12) - 12)/48*100) For the final 'Forgotten Joint Score -12' a high score indicates good outcome.
2,6,12 weeks, and 1 year
Difference in EQ-5D-5L score between the groups
Time Frame: 2,6,12 weeks, and 1 year
5 questions. Every question is scored 1 to 5 where 5 is worse outcome. For example one profile could be' 12233'. As there is no Norwegian index, the EQ5D-5L was converted into a Swedish index score.
2,6,12 weeks, and 1 year
Difference in Oxford Hip Score (OHS) between the groups
Time Frame: 2,6,12 weeks, and 1 year
12 questions. Every question is scored 4 to 0 according to the selected response. Thus the highest score on 48 means a perfectly functioning hip, while a score on 0 means the worst outcome.
2,6,12 weeks, and 1 year
Difference in Timed Up and Go Test (TUG) between the groups
Time Frame: 2,12 weeks, 1 year.
It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down
2,12 weeks, 1 year.
Difference in EQ5D-VAS between the groups
Time Frame: 2,6,12 weeks, and 1 year
Respondents report their perceived health status with a grade ranging from 0 (worst possible health status) to 100 (best possible health status).
2,6,12 weeks, and 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in CK (Creatine Kinase)
Time Frame: preoperatively and day 1,2,3,4 postoperatively.
Measure CK preoperatively and the first 4 postoperative days.
preoperatively and day 1,2,3,4 postoperatively.
Change in CRP (C-Reactive Protein)
Time Frame: preoperatively and day 1,2,3,4 postoperatively.
Measure CRP preoperatively and the first 4 postoperative days.
preoperatively and day 1,2,3,4 postoperatively.
Change in Hb (Hemoglobin)-levels.
Time Frame: preoperatively and day 1,2,3,4 postoperatively.
Measure Hb preoperatively and the first 4 postoperative days.
preoperatively and day 1,2,3,4 postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Øystein B Lian, md phd, Helse Møre og Romsdal Hospital Trust (HF), Kristiansund Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

December 15, 2023

Study Completion (Actual)

December 15, 2023

Study Registration Dates

First Submitted

October 2, 2018

First Submitted That Met QC Criteria

October 3, 2018

First Posted (Actual)

October 4, 2018

Study Record Updates

Last Update Posted (Estimated)

November 1, 2024

Last Update Submitted That Met QC Criteria

October 30, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Femoral Neck Fractures

Clinical Trials on Direct Lateral Approach

Subscribe